![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trilogy International Partners Inc | TSX:TRL | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.24 | 0.20 | 0.275 | 0 | 01:00:00 |
TORONTO, ONTARIO--(Marketwired - Jun 18, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that management is scheduled to present an overview of the Company at the JMP Securities Healthcare Conference at the Westin New York Grand Central, New York on June 24, 2014 at 12:00 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.
For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or Trimel via email at ir@trimelpharmaceuticals.com.
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com???.
Trimel Pharmaceuticals CorporationKenneth HowlingChief Financial Officer(416) 679-0536ir@trimelpharmaceuticals.comwww.trimelpharmaceuticals.com
1 Year Trilogy International Pa... Chart |
1 Month Trilogy International Pa... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions